geneUp	minExonUp	maxExonUp	geneDown	minExonDown	maxExonDown	source	entryDate	sourceEvent	sourceUrls	nctId	title	acronym	genderCriterium	countriesAndCities	hospitalsPerCity	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	efficacyDescription	efficacyDescriptionYear	level	evidenceLevelDetails	direction	evidenceUrls
EGFR	1	2	EGFR	8	9	CKB_EVIDENCE	2021-02-03	fusion	http							Osimertinib			Lung Cancer	X		efficacy evidence A	2024	A	GUIDELINE	RESPONSIVE	http,http
EML4			ALK			CKB_EVIDENCE	2021-02-04	fusion	http							Crizotinib			Lung Cancer	X		efficacy evidence B	2024	A	GUIDELINE	RESPONSIVE	http,http
PCM1			JAK2			CKB_TRIAL		fusion	http	NCT1	study1	study1	male	Germany(Koln;Frankfurt)	Koln(Cellitinnen-Krankenhaus St. Marien),Frankfurt(Burgerhospital Frankfurt)	Ruxolitinib			Leukemia	X			2024	B	GUIDELINE	RESPONSIVE	http,http